Over the last 7 days, the United States market has experienced a slight decline of 1.0%, though it remains up by 15% over the past year, with earnings forecasted to grow by 17% annually. In such an environment, companies that not only demonstrate growth potential but also have high insider ownership can be appealing as they often align management's interests with those of shareholders.
| Name | Insider Ownership | Earnings Growth |
| Uxin (UXIN) | 34.3% | 69.4% |
| Upstart Holdings (UPST) | 14.1% | 59.9% |
| Super Micro Computer (SMCI) | 12.8% | 24.3% |
| Karman Holdings (KRMN) | 15.5% | 52.6% |
| IREN (IREN) | 13.6% | 41.2% |
| Hesai Group (HSAI) | 17.4% | 27.4% |
| ERock (EROC) | 20.1% | 56.3% |
| Corcept Therapeutics (CORT) | 10.8% | 47.8% |
| Cerebras Systems (CBRS) | 11% | 73.7% |
| AppLovin (APP) | 23.2% | 21.7% |
Here's a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Kingstone Companies, Inc., through its subsidiary Kingstone Insurance Company, offers property and casualty insurance products in the United States, with a market cap of $288.39 million.
Operations: The company generates revenue of $224.14 million from its property and casualty insurance products in the United States.
Insider Ownership: 19.7%
Revenue Growth Forecast: 16.4% p.a.
Kingstone Companies demonstrates strong insider confidence with significant recent insider buying and no substantial selling. The company is trading at 36.4% below its estimated fair value, suggesting potential undervaluation. Despite a net loss in the first quarter of 2026, Kingstone's earnings grew by 49.3% over the past year, and its revenue is forecast to grow faster than the US market at 16.4% annually. Recent initiatives like the Ting smart sensor program highlight proactive risk management efforts, while index reclassifications reflect a strategic shift towards defensive positioning.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Prothena Corporation plc is a late-stage clinical biotechnology company dedicated to discovering and developing novel therapies for diseases caused by protein dysregulation, with a market cap of approximately $458.09 million.
Operations: Prothena generates its revenue primarily from its biotechnology segment, totaling $57.94 million.
Insider Ownership: 18.2%
Revenue Growth Forecast: 31.2% p.a.
Prothena exhibits strong growth potential with high insider ownership, evidenced by substantial insider buying in recent months. The company reported impressive first-quarter earnings, with revenue surging to US$51.08 million from US$2.83 million a year ago and net income reaching US$32.72 million. Prothena's revenue is forecast to grow 31.2% annually, outpacing the broader market's 12.6%. Additionally, the FDA granted Fast Track Designation for its promising coramitug antibody for ATTR amyloidosis treatment.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Equity Bancshares, Inc. is a bank holding company for Equity Bank, offering a variety of banking and financial services to both individual and corporate clients, with a market cap of approximately $1.04 billion.
Operations: Equity Bancshares generates revenue through its diverse range of banking and financial services provided to both individual and corporate customers.
Insider Ownership: 14.0%
Revenue Growth Forecast: 20% p.a.
Equity Bancshares demonstrates growth potential with significant insider ownership, evidenced by more shares bought than sold recently. The company reported strong second-quarter results, with net interest income rising to US$73.87 million from US$49.8 million a year ago and net income increasing to US$26.44 million from US$15.26 million. Revenue is forecast to grow 20% annually, surpassing the market's 12.6%. However, profit margins have decreased compared to last year due to large one-off items impacting financials.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com